Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against Pseudomonas aeruginosa by enhancing membrane potential

Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0153923. doi: 10.1128/aac.01539-23. Epub 2024 Mar 12.

Abstract

Murepavadin is a peptidomimetic that specifically targets the lipopolysaccharide transport protein LptD of Pseudomonas aeruginosa. Here, we found that murepavadin enhances the bactericidal efficacies of tobramycin and amikacin. We further demonstrated that murepavadin enhances bacterial respiration activity and subsequent membrane potential, which promotes intracellular uptake of aminoglycoside antibiotics. In addition, the murepavadin-amikacin combination displayed a synergistic bactericidal effect in a murine pneumonia model.

Keywords: Pseudomonas aeruginosa; aminoglycoside antibiotics; murepavadin.

MeSH terms

  • Amikacin* / pharmacology
  • Aminoglycosides / pharmacology
  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Membrane Potentials
  • Mice
  • Microbial Sensitivity Tests
  • Peptides, Cyclic*
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas Infections* / microbiology
  • Pseudomonas aeruginosa
  • Tobramycin / pharmacology

Substances

  • Amikacin
  • murepavadin
  • Anti-Bacterial Agents
  • Aminoglycosides
  • Tobramycin
  • Peptides, Cyclic